The Form 4 filing, a report of an insider's stock trades, was submitted on November 12, 2026. It covers sales from November 9 through November 12, 2026. Ryan Savitz serves as the company's executive vice president, chief financial officer and chief business officer.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-09 |
| Date of Latest Transaction | 2026-11-12 |
| Buy/Sell | sell |
| Transaction Count | 9 |
| Shares Transacted | 124,042 |
| Price | $90.52 |
| Total Transaction Value | $11,228,719.74 |
| Insider | |
| Ticker Symbol | DNTH |
| Company | Dianthus Therapeutics, Inc. /DE/ |
| Insider Name | Savitz Ryan |
| Insider Title | EVP, CFO & CBO |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 0 |
| Position Size Change | 100.00% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of DNTH shares, recorded under transaction code S. The report groups nine sale transactions in one filing.
What was the average price of the transaction?
The average sale price was $90.52 per share across the nine transactions, rounded to the nearest cent.
How did this transaction affect the insider's holdings?
He sold 124,042 shares and reported zero shares owned afterward. The sales represented 100.00% of the shares held before these trades within the reported balance. Details about any other accounts or holdings are unknown.
What's the total transaction value?
The total value was $11,228,719.74 for all nine sales combined, rounded to cents.
Are there any special circumstances around this transaction?
The transaction information includes a reference to a Rule 10b5-1 trading plan. These plans set trading instructions in advance. The filing's footnote text and plan details are unavailable, so it is unclear which of the nine sales the reference covers.
For research purposes only; not investment advice.